A controversial US-funded trial of a hepatitis B vaccine in newborns in Guinea-Bissau has an unclear fate, with various authorities listing it as cancelled, suspended or ongoing.[1] The study was led by Danish researchers Peter Aaby and Christine Stabell Benn of the Bandim Health Project at the University of Southern Denmark, who examined the negative effects of the vaccine given at birth versus delayed for six weeks.[1][3] They planned to enroll 14,000 infants, giving half the hepatitis B vaccine along with the tuberculosis and polio vaccines immediately after birth, while the other half would receive only the tuberculosis and polio vaccines.[1] The primary objective is to determine whether hepatitis B vaccine within one week of birth affects overall morbidity and mortality within 42 days.[1] Secondary endpoints include non-specific effects such as atopic dermatitis by 2 years and neurodevelopmental disorders by 5 years of age.[1][3] The CDC said the study was canceled to take advantage of a vaccine shortage in Guinea-Bissau, but the US Department of Health, the main funder, confirmed to the BMJ that it was continuing.[1] In Guinea-Bissau, children are usually vaccinated against hepatitis B at 6 weeks, but they are planning universal vaccination at birth from 2027-28.[1][3]